FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2180717194> ?p ?o ?g. }

• W2180717194 abstract "Background Glycoprotein (GP) IIb‐IIIa inhibitors are antiplatelet agents that act by antagonising GP IIb‐IIIa receptors on the platelet surface and block the final common pathway to platelet aggregation by preventing the binding of fibrinogen molecules that form bridges between adjacent platelets. Thus, GP IIb‐IIIa inhibitors could favour endogenous thrombolysis by reducing thrombus growth and preventing thrombus re‐formation through competitive inhibition with fibrinogen and, due to their mechanism of action, are likely to have a more profound antiplatelet effect with more rapid onset than conventional antiplatelet agents, such as aspirin or clopidogrel. Currently used in clinical practice for the treatment of individuals with acute coronary syndromes and during coronary angioplasty, GP IIb‐IIIa inhibitors could also be useful for the treatment of people with acute ischaemic stroke. Objectives To assess the use of GP IIb‐IIIa inhibitors in people with acute ischaemic stroke to evaluate whether such treatments (1) reduce the proportion of patients who die or remain dependent, and (2) are sufficiently safe for general use. We wished to examine the effects GP IIb‐IIIa inhibitors alone or in combination with thrombolytic agents. Search methods We searched the Cochrane Stroke Group trials register (last searched 10 June 2013), MEDLINE (1966 to June 2013), EMBASE (1980 to June 2013), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 5, 2013), and major ongoing clinical trials registers (June 2013). We also searched reference lists and contacted trial authors and pharmaceutical companies. Selection criteria We aimed to analyse unconfounded randomised controlled trials (RCTs) of GP IIb‐IIIa inhibitors in the treatment of people with acute ischaemic stroke. Only individuals who started treatment within six hours of stroke onset were included. Data collection and analysis We independently selected trials for inclusion, assessed trial quality and extracted the data. Main results We included four trials involving 1365 participants. Three trials compared the intravenous GP IIb‐IIIa inhibitor Abciximab with intravenous placebo (1215 participants) and one trial compared the intravenous GP IIb‐IIIa inhibitor Tirofiban with intravenous aspirin (150 participants). Treatment with either of these GP IIb‐IIIa inhibitors did not significantly reduce long‐term death or dependency (odds ratio (OR) 0.97, 95% confidence interval (CI) 0.77 to 1.22, for the comparison between Abciximab and placebo; OR 1.00, 95% CI 0.52 to 1.92, for the comparison between Tirofiban and aspirin) and had no effect on deaths from all causes (OR 1.08, 95% CI 0.77 to 1.53, for the comparison between Abciximab and placebo; OR 1.00, 95% CI 0.35 to 2.82, for the comparison between Tirofiban and aspirin). Abciximab was associated with a significant increase in symptomatic intracranial haemorrhage (OR 4.6, 95% CI 2.01 to 10.54) and with a non‐significant increase in major extracranial haemorrhage (OR 1.81, 95% CI 0.96 to 3.41), whereas the only small trial comparing Tirofiban with aspirin showed no increased risk of bleeding complications with Tirofiban (OR 0.32, 95% CI 0.03 to 3.19, for symptomatic intracranial haemorrhage; OR 3.04, 95% CI 0.12 to 75.83, for major extracranial haemorrhages). There was no significant inconsistency across the studies. Authors' conclusions The available trial evidence showed that, for individuals with acute ischaemic stroke, GP IIb‐IIIa inhibitors are associated with a significant risk of intracranial haemorrhage with no evidence of any reduction in death or disability in survivors. These data do not support their routine use in clinical practice. The conclusion is driven by trials of Abciximab, which contributed 89% of the total number of study participants considered." @default.
• W2180717194 created "2016-06-24" @default.
• W2180717194 creator A5005446620 @default.
• W2180717194 creator A5025569076 @default.
• W2180717194 creator A5033206744 @default.
• W2180717194 creator A5062422288 @default.
• W2180717194 creator A5077744101 @default.
• W2180717194 date "2014-03-08" @default.
• W2180717194 modified "2023-10-18" @default.
• W2180717194 title "Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke" @default.
• W2180717194 cites W1595184853 @default.
• W2180717194 cites W1957758434 @default.
• W2180717194 cites W1970934606 @default.
• W2180717194 cites W1985508460 @default.
• W2180717194 cites W1995242999 @default.
• W2180717194 cites W2004993161 @default.
• W2180717194 cites W2009891175 @default.
• W2180717194 cites W2015302937 @default.
• W2180717194 cites W2016234644 @default.
• W2180717194 cites W2025509282 @default.
• W2180717194 cites W2059261222 @default.
• W2180717194 cites W2062275445 @default.
• W2180717194 cites W2076272849 @default.
• W2180717194 cites W2094751695 @default.
• W2180717194 cites W2104736983 @default.
• W2180717194 cites W2107321252 @default.
• W2180717194 cites W2119169574 @default.
• W2180717194 cites W2126930838 @default.
• W2180717194 cites W2127933125 @default.
• W2180717194 cites W2142848477 @default.
• W2180717194 cites W2143086352 @default.
• W2180717194 cites W2143642806 @default.
• W2180717194 cites W2317947810 @default.
• W2180717194 cites W4210980547 @default.
• W2180717194 cites W4230152170 @default.
• W2180717194 cites W4238698686 @default.
• W2180717194 doi "https://doi.org/10.1002/14651858.cd005208.pub3" @default.
• W2180717194 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24609741" @default.
• W2180717194 hasPublicationYear "2014" @default.
• W2180717194 type Work @default.
• W2180717194 sameAs 2180717194 @default.
• W2180717194 citedByCount "60" @default.
• W2180717194 countsByYear W21807171942013 @default.
• W2180717194 countsByYear W21807171942014 @default.
• W2180717194 countsByYear W21807171942015 @default.
• W2180717194 countsByYear W21807171942016 @default.
• W2180717194 countsByYear W21807171942017 @default.
• W2180717194 countsByYear W21807171942018 @default.
• W2180717194 countsByYear W21807171942019 @default.
• W2180717194 countsByYear W21807171942020 @default.
• W2180717194 countsByYear W21807171942021 @default.
• W2180717194 countsByYear W21807171942022 @default.
• W2180717194 countsByYear W21807171942023 @default.
• W2180717194 crossrefType "journal-article" @default.
• W2180717194 hasAuthorship W2180717194A5005446620 @default.
• W2180717194 hasAuthorship W2180717194A5025569076 @default.
• W2180717194 hasAuthorship W2180717194A5033206744 @default.
• W2180717194 hasAuthorship W2180717194A5062422288 @default.
• W2180717194 hasAuthorship W2180717194A5077744101 @default.
• W2180717194 hasBestOaLocation W21807171941 @default.
• W2180717194 hasConcept C126322002 @default.
• W2180717194 hasConcept C127413603 @default.
• W2180717194 hasConcept C168563851 @default.
• W2180717194 hasConcept C2776335557 @default.
• W2180717194 hasConcept C2776478404 @default.
• W2180717194 hasConcept C2776572282 @default.
• W2180717194 hasConcept C2777628954 @default.
• W2180717194 hasConcept C2777698277 @default.
• W2180717194 hasConcept C2777849778 @default.
• W2180717194 hasConcept C2777871224 @default.
• W2180717194 hasConcept C2779581417 @default.
• W2180717194 hasConcept C2780400711 @default.
• W2180717194 hasConcept C2780645631 @default.
• W2180717194 hasConcept C2781056559 @default.
• W2180717194 hasConcept C2781362458 @default.
• W2180717194 hasConcept C2909112448 @default.
• W2180717194 hasConcept C2909817843 @default.
• W2180717194 hasConcept C500558357 @default.
• W2180717194 hasConcept C535046627 @default.
• W2180717194 hasConcept C71924100 @default.
• W2180717194 hasConcept C78519656 @default.
• W2180717194 hasConcept C98274493 @default.
• W2180717194 hasConceptScore W2180717194C126322002 @default.
• W2180717194 hasConceptScore W2180717194C127413603 @default.
• W2180717194 hasConceptScore W2180717194C168563851 @default.
• W2180717194 hasConceptScore W2180717194C2776335557 @default.
• W2180717194 hasConceptScore W2180717194C2776478404 @default.
• W2180717194 hasConceptScore W2180717194C2776572282 @default.
• W2180717194 hasConceptScore W2180717194C2777628954 @default.
• W2180717194 hasConceptScore W2180717194C2777698277 @default.
• W2180717194 hasConceptScore W2180717194C2777849778 @default.
• W2180717194 hasConceptScore W2180717194C2777871224 @default.
• W2180717194 hasConceptScore W2180717194C2779581417 @default.
• W2180717194 hasConceptScore W2180717194C2780400711 @default.
• W2180717194 hasConceptScore W2180717194C2780645631 @default.
• W2180717194 hasConceptScore W2180717194C2781056559 @default.
• W2180717194 hasConceptScore W2180717194C2781362458 @default.
• W2180717194 hasConceptScore W2180717194C2909112448 @default.
• W2180717194 hasConceptScore W2180717194C2909817843 @default.
• W2180717194 hasConceptScore W2180717194C500558357 @default.

• next